Join our daily newsletter At The Bell to receive exclusive market insights
- Invex Therapeutics (IXC) appoints a group chairperson for its IIH EVOLVE phase three clinical trial for treating idiopathic intracranial hypertension
- Professor Michael Wall will assume the role of Trial Steering Group Chairperson, overseeing the study involving a once-weekly administration of Presendin
- Invex says it’s delighted Professor Wall has joined its global trial on a condition where approved therapies are lacking
- Invex Therapeutics was down 3.57 per cent to $0.68 per share at 12:54 pm AEDT
Invex Therapeutics (IXC) has appointed a group chairperson for its IIH EVOLVE phase three clinical trial for treating idiopathic intracranial hypertension (IIH).
Professor Michael Wall will assume the role of Trial Steering Group Chairperson, where he will oversee a study involving a once weekly administration of Presendin compared to a placebo for treating the disabling daily headaches and compression of the optic nerve.
The trial is a randomised, double-blind study that will randomise 240 patients with newly diagnosed IIH to determine the efficacy and safety of Presendin versus a placebo over a 24 week period.
The primary endpoint of the trial is to see a change in intracranial pressure as measured by lumbar puncture, both at baseline and at the end of the trial.
Dr Wall is a Professor of ophthalmology and neurology at the University of Iowa College of Medicine, and Director of the Iowa Visual Field Reading Centre.
Professor Alexandra Sinclair, Executive Director and Chief Scientific Officer of Invex said the company is delighted Professor Wall has joined its global trial in IIH.
“We certainly welcome the opportunity to work with Professor Wall on this important Phase III clinical trial in IIH, where approved therapies are lacking,” Professor Sinclair said.
Invex Therapeutics was down 3.57 per cent to $0.68 per share at 12:54 pm AEDT.
